Last edited by Mezill
Friday, August 7, 2020 | History

2 edition of Role of non-transferrin bound iron in acute leukaemia and sickle cell disease. found in the catalog.

Role of non-transferrin bound iron in acute leukaemia and sickle cell disease.

Sukhjinder Singh Marwah

Role of non-transferrin bound iron in acute leukaemia and sickle cell disease.

by Sukhjinder Singh Marwah

  • 60 Want to read
  • 22 Currently reading

Published by University of Wolverhampton in Wolverhampton .
Written in English


Edition Notes

Dissertation (Ph.D.) - University of Wolverhampton 2001.

ID Numbers
Open LibraryOL18647724M

Role of Non-Transferrin-Bound Iron in the pathogenesis of cardiotoxicity in patients with ST-Elevation Myocardial Infarction assessed by Cardiac Magnetic Resonance Imaging Article Aug Iron is a crucial regulator of cell function, but its role in human macrophage immunometabolism is only partially understood. Pereira et al. show that acute iron deprivation in human macrophages causes anti-inflammatory immune and metabolic responses, and acute iron deprivation in rats reduces the severity of macrophage-driven renal inflammation.

  Sickle cell disease is a group of inherited genetic disordersin which hemoglobin polymerizes when deoxygenated,leading to hemolysis, blood vessel obstruction by sickledRBCs, and tissue hypoxia. Markers of iron metabolism (plasma NTBI, labile iron, hepcidin, transferrin, monocyte SLC40A1 [ferroportin]), erythropoiesis (growth differentiation fac soluble transferrin receptor) and tissue hypoxia (erythropoietin) were compared in patients with Thalassaemia Major (TM), Sickle Cell Disease and Diamond-Blackfan Anaemia (DBA), with.

Non‐transferrin‐bound iron (NTBI) was evaluated as an index of iron overload in a cross‐sectional randomised study in 74 non‐transfused patients with thalassaemia intermedia (TI). Mean NTBI (292 ± 343 μmol/l), serum ferritin ( ± ng/ml) and liver iron concentration (LIC; 90 ± 74 mg Fe/g dry weight) were increased. A 3-year-old girl was being treated for acute lymphoblastic leukaemia (ALL) on the paediatric oncology ward. She had required numerous red cell and platelet transfusions during induction chemotherapy. She was the youngest of four siblings, two of which suffered from beta-thalassaemia. Her mother wanted to know why her daughter was not on treatment to reduce the iron from all the blood.


Share this book
You might also like
Necropsy and liver histopathology for fish sampled adjacent to the Barbers Point Ocean Outfall and the Maunalua Bay reference station, Oʻahu, Hawaiʻi, January 2009

Necropsy and liver histopathology for fish sampled adjacent to the Barbers Point Ocean Outfall and the Maunalua Bay reference station, Oʻahu, Hawaiʻi, January 2009

The chemical theatre

The chemical theatre

Elementary algebra

Elementary algebra

Hearing the New Testament

Hearing the New Testament

Kon Tiki

Kon Tiki

Targeting rules vs. instrument rules for monetary policy

Targeting rules vs. instrument rules for monetary policy

Boxes

Boxes

practical manual of diabetic foot care

practical manual of diabetic foot care

The Englishman in Paris

The Englishman in Paris

Western Civilization, Volume 2 6th Edition And Atlas 1998

Western Civilization, Volume 2 6th Edition And Atlas 1998

Things not reveald

Things not reveald

The thing on the wing can sing

The thing on the wing can sing

Role of non-transferrin bound iron in acute leukaemia and sickle cell disease by Sukhjinder Singh Marwah Download PDF EPUB FB2

Role of non-transferrin bound iron in acute leukaemia and sickle cell disease. (Thesis) Marwah SS. Publisher: University of Wolverhampton [] Metadata Source: The British Library Type: Thesis. Abstract. No abstract supplied. Menu. Formats. Abstract. EThOS. About. About Europe PMC Author: Marwah Ss.

Role of non-transferrin bound iron in acute leukaemia and sickle cell disease Author: Marwah, S. ISNI: Awarding Body: University of Wolverhampton Current Institution: University of Wolverhampton Date of Award: Availability of Full Text.

We analyzed appearance of non transferrin bound iron (NTBI) in 30 transplant eligible patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) during conventional chemotherapy treatment program and evaluated possible relationship with transfusional body iron intake, iron parameters and clinical by: First, they clearly demonstrate that HIO is very common in acute leukemia/MDS patients undergoing HSCT, with a prevalence of 85%.

It is also clear that iron overload in this population is at least in large part because of red cell transfusion, as the number of transfused units is the single best predictor of elevated LIC in multivariable by: Background: Blood transfusions are the standard of care in β thalassemia and transfusions are also indicated in sickle cell disease (SCD) patients with hypersplenism, recurrent vaso‐occlusive crises and for stroke prevention.

Iron overload caused by blood transfusions in thalassemia and in SCD may affect morbidity and mortality. Recent studies of iron overload in SCD suggest that the Cited by:   1. Introduction. Transfusional iron overload (IO) pre-allogeneic hematopoietic stem cell transplantation (HSCT) has been associated with reduced overall survival (OS), increased non relapse mortality, increased incidence of graft-versus-host disease, infectious complications, and veno-occlusive transferrin bound iron (NTBI), a toxic low molecular weight fraction of iron, is.

Iron overload (IO) in the heart is a life‐threatening complication in transfusion‐dependent patients with thalassaemia major (TM) and to a lesser extent in sickle cell disease (SCD), while no data are available in patients with sickle/β 0 ‐thalassaemia.

Iron deposition in the heart, liver and pancreas was assessed using T2* MRI sequences, as well as free iron species assays – non.

A Belotti, L Duca, L Borin, S Realini, R Renso, M Parma, et transferrin bound iron (NTBI) in acute leukemias throughout conventional intensive chemotherapy: kinetics of its appearance and potential predictive role in infectious complications.

Blood transfusion plays a prominent role in the management of patients with sickle cell disease (SCD), but causes significant iron overload. As transfusions are used to treat the severe complications of SCD, it remains difficult to distinguish whether organ damage is a consequence of iron overload or is due to the complications treated by transfusion.

Hepatocytes represent the main depot for iron storage in normal conditions and in non-transfusional iron overload. Although the TF cycle may be involved in hepatocyte iron acquisition to some extent, non–transferrin-bound iron (NTBI) uptake pathways become particularly important when serum iron levels exceed TF binding capac   Evaluation of the impact of iron overload in patients requiring chronic transfusion.

In thalassaemia the negative impact of iron overload on survival has been fully established, but this is not the case for other diseases requiring chronic transfusion support (Table I).In patients with myelodysplastic syndromes or acute leukaemia and in haematopoietic stem cell transplant recipients, the.

Role of non-transferrin bound iron in iron overload and liver dysfunction in long term survivors of acute leukaemia and bone marrow transplantation. J Clin Pathol ; – Role of non-transferrin bound iron in iron overload and liver dysfunction in long term survivors of acute leukaemia and bone marrow transplantation.

P Harrison, J R Neilson, S S Marwah, Non-transferrin bound iron may also be a more specific indicator of iron. We analyzed appearance of Non Transferrin Bound Iron (NTBI) in 30 transplant eligible patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) during conventional.

The value of nontransferrin-bound iron (NTBI) as an index of iron overload in patients with thalassemia has been evaluated; however, data in patients with sickle cell disease (SCD) is limited.

Role of non-transferrin bound iron in acute leukaemia and sickle cell disease. By S.S. Marwah. Abstract. Available from British Library Document Supply Centre- DSC:DXN / BLDSC - British Library Document Supply CentreSIGLEGBUnited Kingdo.

Studies in the MDS population suggest that iron overload mediated by NTBI/LPI aggravates genomic instability of this pre‐leukemic state hence contributing to the development of AML and accelerating transformation to acute leukemia, as well as plays a role in disease progression, relapse, and survival in patients following allogeneic.

Harrison P, Neilson JR, Marwah SS et al. Role of non-transferrin bound iron in iron overload and liver dysfunction in long term survivors of acute leukaemia and bone marrow transplantation.

J Clin. Hassan M, Hasan S, Giday S, et al. Hepatitis C virus in sickle cell disease. J Natl Med Assoc. Oct. 95(10) Halonen P, Mattila J, Suominen P, et al. Iron overload in children who are treated for acute lymphoblastic leukemia estimated by liver siderosis and serum iron parameters.

Pediatrics. Jan. (1)   Full iron stores, inflammation or mutations in TMPRSS-6 lead to hepcidin upregulation in hepatocytes. Hepcidin is secreted in the circulation and binds to ferroportin, leading to ubiquitination and degradation of the molecule, thus limiting export of iron in the circulation.

Non-transferrin-bound iron appears in the circulation (B). PhD Role of Non-Transferrin bound Iron in Acute Leukaemia and Sickle cell disease. – Aston University.

Aston University Bachelor of Science (BSc) Biochemistry and Pharmacology. Languages. Punjabi. View Dr Sukhjinder Singh Marwah’s full profile to.

See who you know in common;Title: Clinical Scientist at Sandwell and .Non-transferrin-bound iron and hepatic dysfunction in African dietary iron overload. J Gastroenterol Hepatol ; Harrison P, Neilson JR, Marwah SS, Madden L, Bareford D, Milligan DW.

Role of non-transferrin bound iron in iron overload and liver dysfunction in long term survivors of acute leukaemia and bone marrow transplantation.

Disease type and stage, prior chemotherapy, and HFE genotype did not seem to play a significant role in iron overload in this patient population, except for the association of prior therapy with transfusion burden.

It is also apparent that significant HIO is found in a large proportion of those patients (42% in our cohort).